Jenburkt Pharmaceuticals Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Medico Remedies

Jenburkt Pharma

Haleos Labs Limi

Medicamen Biotec

Kilitch Drugs

Kopran

Shree Ganesh Rem

Albert David

Kerala Ayurveda

Solara Active PP

Influx Health.

Why is Jenburkt Pharmaceuticals Ltd. ?

High Management Efficiency with a high ROE of 18.99%

Company has a low Debt to Equity ratio (avg) at 0 times

Poor long term growth as Net Sales has grown by an annual rate of 7.31% and Operating profit at 15.91% over the last 5 years

Positive results in Sep 25

NET SALES(Q) Highest at Rs 45.56 cr
PBDIT(Q) Highest at Rs 13.10 cr.
OPERATING PROFIT TO NET SALES(Q) Highest at 28.75%

With ROE of 18, it has a Expensive valuation with a 2.7 Price to Book Value

The stock is trading at a fair value compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -10.05%, its profits have risen by 8.9% ; the PEG ratio of the company is 1.7

Majority shareholders : Non Institution

Underperformed the market in the last 1 year

Even though the market (BSE500) has generated returns of 1.94% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -10.05% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Jenburkt Pharma should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jenburkt Pharma for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Jenburkt Pharma

-10.05%

-0.24

42.07%

Sensex

4.78%

0.40

11.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.31%

EBIT Growth (5y)

15.91%

EBIT to Interest (avg)

30.71

Debt to EBITDA (avg)

0.11

Net Debt to Equity (avg)

-0.04

Sales to Capital Employed (avg)

1.00

Tax Ratio

28.06%

Dividend Payout Ratio

25.99%

Pledged Shares

Institutional Holding

0.12%

ROCE (avg)

35.97%

ROE (avg)

18.99%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.67

EV to EBIT

12.40

EV to EBITDA

11.50

EV to Capital Employed

2.74

EV to Sales

3.02

PEG Ratio

1.66

Dividend Yield

ROCE (Latest)

22.13%

ROE (Latest)

18.04%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

NET SALES(Q)

Highest at Rs 45.56 cr

PBDIT(Q)

Highest at Rs 13.10 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 28.75%

PBT LESS OI(Q)

At Rs 12.25 cr has Grown at 33.6% (vs previous 4Q average

PAT(Q)

Highest at Rs 10.16 cr.

EPS(Q)

Highest at Rs 23.04

-2What is not working for the Company

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.70 times

Loading Valuation Snapshot...

Here's what is working for Jenburkt Pharma

Net Sales - Quarterly

Highest at Rs 45.56 cr

in the last five quarters

MOJO Watch

Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly

Highest at Rs 13.10 cr.

in the last five quarters

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly

Highest at 28.75%

in the last five quarters

MOJO Watch

Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly

Highest at Rs 12.25 cr.

in the last five quarters

MOJO Watch

Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 12.25 cr has Grown at 33.6% (vs previous 4Q average)

over average PBT of the previous four quarters of Rs 9.17 Cr

MOJO Watch

Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly

Highest at Rs 10.16 cr.

in the last five quarters

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly

At Rs 10.16 cr has Grown at 25.3% (vs previous 4Q average)

over average PAT of the previous four quarters of Rs 8.11 Cr

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly

Highest at Rs 23.04

in the last five quarters

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Jenburkt Pharma

Debtors Turnover Ratio- Half Yearly

Lowest at 0.70 times

in the last five half yearly periods

MOJO Watch

Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio

Non Operating Income - Quarterly

Highest at Rs 2.08 cr

in the last five quarters

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating Income